Heritage Pharma Announces The Return Of Tetracycline HCI Capsules
EATONTOWN, N.J., Oct. 21, 2013 /PRNewswire/ -- Heritage Pharmaceuticals Inc. ("Heritage") announced the immediate availability of Tetracycline HCl Capsules, USP in 250 and 500 mg strengths. This product is the AB rated generic equivalent to the antibiotic Achromycin V and adds to Heritage's robust portfolio of generic oral solid products. Tetracycline capsules have been on the FDA drug shortage list for the past two years and Heritage is the first generic pharmaceutical manufacturer to reintroduce the product.
About Tetracycline HCl
Tetracycline HCl is indicated for the treatment of various bacterial infections. The package insert, which is available at www.heritagepharma.com, contains detailed information about the indications, complete side effect profile and prescribing information.
About Heritage
Heritage Pharmaceuticals Inc. is a specialty pharmaceutical company engaged in the development, manufacturing, sales and marketing of generic and legacy branded pharmaceutical products for the U.S. prescription drug market. Since inception, our customers have experienced the benefits of our continuous product expansion and global alliance network that has produced an impressive portfolio of over 150 products spanning multiple dosage forms. Heritage's products cover a number of therapeutic categories, including but not limited to: oncology, cardiovascular, metabolic disease, anti-infective and pain management. Whether its oral solids or complex injectables, the Heritage portfolio is poised to continue to rapidly expand and deliver the Value Driven Medicine required to keep our customers competitive in the marketplace. Let our formula of high quality and consistent supply work for you as we continue to provide affordable healthcare solutions to the U.S. consumer.
SOURCE Heritage Pharmaceuticals Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article